• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

MOLECULAR PARTNERS N (MOLN)

Sell: 3.02 CHF|Buy: 3.50 CHF|Change: 0.06 (1.80%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPintherapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Address




Website

https://www.molecularpartners.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Molecular Partners AG Annual General Meeting for 20272027-04-14T09:00:00
Molecular Partners AG Fourth Quarter Earnings Conference Call for 20262027-03-12T16:00:00
Molecular Partners AG Fourth Quarter Earnings Results for 20262027-03-12T00:00:00
Molecular Partners AG Annual Report for 20262027-03-12T00:00:00
Molecular Partners AG Second Quarter Earnings Conference Call for 20262026-08-25T00:00:00
Molecular Partners AG Second Quarter Earnings Result for 20262026-08-25T00:00:00
Molecular Partners AG Annual General Meeting for 20262026-04-14T09:00:00

Previous key dates

NameKey Date
Molecular Partners AG Annual General Meeting for 20262026-04-14T09:00:00
Molecular Partners AG Fourth Quarter Earnings Conference Call for 20252026-03-12T16:00:00
Molecular Partners AG Fourth Quarter Earnings Result for 20252026-03-12T00:00:00
Molecular Partners AG Annual Report for 20252026-03-12T00:00:00
Leerink Partners Global Healthcare Conference 20262026-03-09T16:20:00
TD Cowen 46th Annual Health Care Conference2026-03-02T14:30:00
MP0712: New patient imaging and dosimetry data, update on Phase 1/2a study2026-02-02T08:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-15T10:30:00
Molecular Partners AG Second Quarter Earnings Conference Call for 20252025-08-25T00:00:00
Molecular Partners AG Second Quarter Earnings Result for 20252025-08-25T00:00:00
Molecular Partners AG Unknown TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA2025-05-28T10:00:00
H.C. Wainwright 3rd Annual BioConnect Investor Conference2025-05-20T15:30:00
Molecular Partners AG Annual General Meeting for 20252025-04-16T09:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.